Kbc Group Nv Ascendis Pharma A/S Transaction History
Kbc Group Nv
- $37 Billion
- Q2 2025
A detailed history of Kbc Group Nv transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Kbc Group Nv holds 356 shares of ASND stock, worth $73,054. This represents 0.0% of its overall portfolio holdings.
Number of Shares
356
Previous 411
13.38%
Holding current value
$73,054
Previous $64,000
4.69%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ASND
# of Institutions
282Shares Held
60MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.11 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.12 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$1.02 Billion15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$909 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$874 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.5B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...